Health

HonorHealth deploys Qventus AI against a $150 million-a-year Medicaid hole by 2032

The nine-hospital Phoenix system expects federal Medicaid changes to strip more than $150 million a year from its margins by 2032. Its September deal with Qventus shows who hospital AI budgets are now written for: operators defending margin.

In this storyQventus
Vincent JiangVincent Jiang · 2 min read
Share
Kim Post, chief operating officer of HonorHealth
1 / 6Slide 1 of 6
Kim Post, HonorHealth's chief operating officer, whose teams deploy the Qventus AI teammates inside the Epic record

Patients are already slipping off Medicaid

HonorHealth, a nonprofit system running nine acute-care hospitals across greater Phoenix, is watching patients shift from Medicaid coverage into self-pay ahead of federal work requirements that begin in 2027 under the reconciliation law known as HR 1 1.

CEO Todd LaPorte now expects more than $150 million in annual margin deterioration by 2032 from federal legislative and CMS policy changes 1. The system collects about $4.5 billion a year at a 1 to 2 percent operating margin, or $45 million to $90 million of operating income, and it ran at -0.2 percent in 2025 1.

The projected annual loss exceeds HonorHealth's entire operating income

  • Estimate
$0M$50M$100M$150MOperating income at 1% margin$45MOperating income at 2% margin$90MProjected annual margin loss by 2032$150M
Data
Value
Operating income at 1% margin$45M
Operating income at 2% margin$90M
Projected annual margin loss by 2032 (estimate)$150M
CEO-estimated operating income on about $4.5B revenue versus projected annual margin deterioration by 2032 from federal legislative and CMS policy changes, in millions of dollars. Source: Becker's Hospital Review interview with Todd LaPorte, October 2026.1

The September purchase is margin defense

On September 17, Qventus, a privately held San Francisco company selling AI automation for hospital operations, named HonorHealth the latest client of its AI Solution Factory, a model that embeds Qventus engineers with hospital clinicians and IT to build custom AI teammates that act inside HonorHealth's Epic electronic health record 2. HonorHealth COO Kim Post says each solution already deployed has reinforced the confidence to go deeper 2.

LaPorte frames the buy plainly: not a silver bullet, but part of the solution 1. Qventus has raised $201 million across six rounds, including a $105 million round led by the investment firm KKR in January 2025 34.

The receipts are expansion, and they are vendor-reported

Nearly half of Qventus clients, across more than 150 hospital facilities, now run more than one of its modules 28. Allina Health, a Minneapolis nonprofit and the Factory's first client in December 2025, unlocked 689 hours of robotics capacity and a near 6x annualized ROI in 2025 5.

OhioHealth, based in Columbus, expanded in July after Qventus saved nearly 13,000 excess hospital days and $5.1 million, and only after EHR-native tools failed to deliver the surgical growth it wanted 6. Clients using the malnutrition coding module launched in February captured $17.1 million in annualized reimbursement by August 7. Every figure in this section is the vendor's.

The hole is bigger than the software

LaPorte's own arithmetic caps what automation can do here: the projected annual loss is larger than his system's entire operating income at the top of its range 1. Qventus's growth case rests on that squeeze continuing.

Watch the second module

Work requirements start in 2027, the year John Neil succeeds LaPorte as CEO on March 1 1. The tell is expansion revenue: if Qventus keeps landing the second and third module inside the same systems, the Medicaid squeeze is writing the hospital AI budget.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Eli Lilly files 11 suits against retatrutide sellers before the drug even wins FDA approval

    Eleven federal suits target sellers of an unapproved obesity drug before launch day. With Q3 earnings on October 29 showing 60% volume growth against a 13% price decline, Lilly is buying court protection for launch-year revenue.

    Health

    Eli Lilly's olomorasib could win first-line KRAS lung cancer, and no one is trading the option

    The ESMO data put Lilly's olomorasib on track to be the first targeted therapy sold into newly diagnosed KRAS G12C lung cancer, with Keytruda riding along in both combinations. The randomized proof lands next year, and nobody is trading the option yet.

    Health

    Prosper's $108 billion uncollected-care claim shrinks by half under its own no-show and denial rates

    The a16z-backed voice-agent vendor says specialty practices leave $125,000 per physician uncollected each year. Run the report's own no-show, denial and collection rates back through its flagship example and the number shrinks by roughly half, and most of what remains is a transfer from payers and patients, not new money.

    Health

    OpenEvidence's prior-auth letters no better than ChatGPT's in Mayo test; $15 billion buys its distribution

    A Mayo Clinic head-to-head and a Nature Medicine study put the quality of OpenEvidence's answers on the record in one week: good enough to use, no longer uniquely good. At $15 billion, investors are paying for distribution, and distribution now has company.

    Health

    Eli Lilly's 79% ovarian cancer response rate came from a dose its Phase 3 won't use

    Lilly's headline response rate at ESMO was measured at 4 mg/kg; the Phase 3 runs 3 mg/kg, and the combination result at that dose is unpublished. A day earlier, Genmab posted a positive Phase 3 on the same payload class.

    Health

    Molina's 10-Q moves its two biggest Medicaid wins past the 2027 recovery the Street is pricing

    The 10-Q moves the Georgia and Texas wins to late 2027 or 2028 while the Street raises targets on 2027 rates; the Florida children's contract is guided to a $1.50-per-share quarterly loss and about 700 autism providers say they are unpaid. The recovery-year revenue arrives after the recovery year.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.